Aurelio Maggio

Summary

Country: Italy

Publications

  1. ncbi Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial
    Aurelio Maggio
    Divisione di Ematologia II e Unità di Ricerca Piera Cutino, Azienda Ospedaliera V Cervello, Palermo, Italy
    Blood Cells Mol Dis 28:196-208. 2002
  2. ncbi Allele-specific transcription of fetal genes in primary erythroid cell cultures from Lepore and deltabeta degrees thalassemia patients
    Rosalba Di Marzo
    Unità di Ricerca P Cutino, Ematologia II, Palermo, Italy
    Exp Hematol 33:1363-70. 2005
  3. ncbi Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload
    Alessia Pepe
    MRI Laboratory, Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy
    J Magn Reson Imaging 23:662-8. 2006
  4. ncbi Light and shadows in the iron chelation treatment of haematological diseases
    Aurelio Maggio
    Haematology II with Thalassaemia and Regional Coordination Centre for the Network on Haemoglobinopathies, Hospital V Cervello, Palermo, Italy
    Br J Haematol 138:407-21. 2007
  5. doi Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Br J Haematol 145:245-54. 2009
  6. pmc In Utero Haematopoietic Stem Cell Transplantation (IUHSCT)
    Maria Concetta Renda
    U O C Ematologia II con Talassemia, Ospedali Riuniti Villa Sofia Cervello, Palermo
    Mediterr J Hematol Infect Dis 1:e2009031. 2009
  7. ncbi A critical review of non invasive procedures for the evaluation of body iron burden in thalassemia major patients
    Aurelio Maggio
    Division of Haematology II with Thalassemia, Hospital V Cervello, Via Trabucco n 180, and Radiology Institute, University of Palermo, Policlinico P Giaccone, Palermo, Italy
    Pediatr Endocrinol Rev 6:193-203. 2008
  8. doi Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Blood Cells Mol Dis 47:166-75. 2011
  9. doi Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
    Aurelio Maggio
    U O C Ematologia II con Talassemia, Ospedali Riuniti P O Cervello Palermo, Palermo, Italy
    Am J Hematol 87:732-3. 2012
  10. doi Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Blood Cells Mol Dis 42:247-51. 2009

Collaborators

Detail Information

Publications51

  1. ncbi Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial
    Aurelio Maggio
    Divisione di Ematologia II e Unità di Ricerca Piera Cutino, Azienda Ospedaliera V Cervello, Palermo, Italy
    Blood Cells Mol Dis 28:196-208. 2002
    ..These findings suggest that deferiprone may be as effective as deferoxamine in the treatment of thalassemia major with few mild and reversible side effects...
  2. ncbi Allele-specific transcription of fetal genes in primary erythroid cell cultures from Lepore and deltabeta degrees thalassemia patients
    Rosalba Di Marzo
    Unità di Ricerca P Cutino, Ematologia II, Palermo, Italy
    Exp Hematol 33:1363-70. 2005
    ..Our goal was to address the question of whether the allele carrying the deltabeta degrees deletion is responsible for high level of fetal hemoglobin (HbF) production...
  3. ncbi Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload
    Alessia Pepe
    MRI Laboratory, Institute of Clinical Physiology, Consiglio Nazionale delle Ricerche, Pisa, Italy
    J Magn Reson Imaging 23:662-8. 2006
    ..To assess the tissue iron concentration of the left ventricle (LV) using a multislice, multiecho T2* MR technique and a segmental analysis...
  4. ncbi Light and shadows in the iron chelation treatment of haematological diseases
    Aurelio Maggio
    Haematology II with Thalassaemia and Regional Coordination Centre for the Network on Haemoglobinopathies, Hospital V Cervello, Palermo, Italy
    Br J Haematol 138:407-21. 2007
    ..Finally, if iron chelation is required for sickle-cell disorders or myelodysplastic syndromes, the current data support the use of deferoxamine treatment...
  5. doi Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Br J Haematol 145:245-54. 2009
    ....
  6. pmc In Utero Haematopoietic Stem Cell Transplantation (IUHSCT)
    Maria Concetta Renda
    U O C Ematologia II con Talassemia, Ospedali Riuniti Villa Sofia Cervello, Palermo
    Mediterr J Hematol Infect Dis 1:e2009031. 2009
    ..There are three possible barriers to engraftment following IUHSCT: limited space in the fetus due to host-cell competition; the large number of donor cells needed, and the immunological asset of recipient...
  7. ncbi A critical review of non invasive procedures for the evaluation of body iron burden in thalassemia major patients
    Aurelio Maggio
    Division of Haematology II with Thalassemia, Hospital V Cervello, Via Trabucco n 180, and Radiology Institute, University of Palermo, Policlinico P Giaccone, Palermo, Italy
    Pediatr Endocrinol Rev 6:193-203. 2008
    ....
  8. doi Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Blood Cells Mol Dis 47:166-75. 2011
    ..01 and p<0.00001, respectively). These findings do not support any specific chelation treatment. The literature shows risks of bias, and additional larger and longer trials are needed...
  9. doi Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients
    Aurelio Maggio
    U O C Ematologia II con Talassemia, Ospedali Riuniti P O Cervello Palermo, Palermo, Italy
    Am J Hematol 87:732-3. 2012
    ....
  10. doi Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies
    Aurelio Maggio
    U O C Ematologia II con Talassemia, A O V Cervello, Palermo, Italy
    Blood Cells Mol Dis 42:247-51. 2009
    ..013). In conclusion, the results of this study show that the risk factors for predicting mortality in patients with thalassemia major are deferoxamine-treatment, complications, and the interaction effect of sex and age...
  11. doi Significance of borderline hemoglobin A2 values in an Italian population with a high prevalence of beta-thalassemia
    Antonino Giambona
    U O C Ematologia II con Talassemia, Azienda Ospedaliera Vincenzo Cervello, Via Trabucco 180, Palermo, Italy
    Haematologica 93:1380-4. 2008
    ..These data support the necessity to investigate these cases at a molecular level, particularly if the partner is a carrier of beta-thalassemia...
  12. doi Hb Southern Italy: coexistence of two missence mutations (the Hb Sun Prairie alpha2 130 Ala --> Pro and Hb Caserta alpha2 26 Ala --> Thr) in a single HBA2 gene
    Cristina Passarello
    U O C Ematologia II con Talassemia, Ospedale Vincenzo Cervello, Palermo, Italy
    Br J Haematol 143:138-42. 2008
    ..We report the clinical phenotype and molecular study of this new double mutant form of haemoglobin in heterozygous and homozygous subjects, as well as in association with alpha degrees delectional thalassemia...
  13. doi Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients
    Paolo Rigano
    U O C Ematologia II, Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
    Br J Haematol 151:509-15. 2010
    ..The mechanism of this loss of response to HC remains to be determined...
  14. doi Feasibility of DNA diagnosis of haemoglobinopathies on coelocentesis
    Antonino Giambona
    U O C Ematologia II con Talassemia, AO O R Villa Sofia Cervello, via Trabuco 180, Palermo, Italy
    Br J Haematol 153:268-72. 2011
    ..The results of this study suggest that reliable diagnosis of thalassemia syndromes can be performed from 7 weeks gestation by celocentesis. Further work is necessary to demonstrate the safety of celocentesis before widespread use...
  15. doi Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac death
    Aurelio Maggio
    U O C Ematologia II, AOR Villa Sofia V Cervello, Palermo, Italy
    Blood Cells Mol Dis 50:241-6. 2013
    ..0022). However, because of limitations related to the study design, such findings should be confirmed in a large long-term prospective clinical trial...
  16. doi Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients
    Roberta Calzolari
    Unità di Ricerca P Cutino, Ematologia II, Universita degli Studi di Palermo, Palermo, Italy
    Br J Haematol 141:720-7. 2008
    ..These observations provide evidences that the molecular mechanism of action is involved in the increase of fetal haemoglobin production by HC...
  17. doi Embryo-fetal erythroid megaloblasts in the human coelomic cavity
    Maria Concetta Renda
    Hematology II Thalassemia, Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
    J Cell Physiol 225:385-9. 2010
    ..The ease of access of the coelomic cavity could allow the development of novel strategies for diagnostic or therapeutic purposes by ultrasound imaging and ultrasound-guided puncture...
  18. ncbi Analysis of delta-globin gene alleles in the Sicilian population: identification of five new mutations
    Antonino Giambona
    U O Ematologia II con Talassemia, Azienda Ospedaliera Vincenzo Cervello, Via Trabucco 180, 90146, Palermo, Italy
    Haematologica 91:1681-4. 2006
    ..422C-->T). This study suggests that delta-globin gene defects are very common in Sicily. Thus, these mutations need to be considered during beta-thalassemia screening to avoid false negative results in the detection of at-risk couples...
  19. doi Identification of three new nucleotide substitutions in the β-globin gene: laboratoristic approach and impact on genetic counselling for beta-thalassaemia
    Margherita Vinciguerra
    Department of Haematology for Rare Diseases of Blood and Blood forming Organs, Regional Reference Laboratory for Screening and Prenatal Diagnosis of Haemoglobinopathies, Villa Sofia Cervello Hospital, Palermo, Italy
    Eur J Haematol 92:444-9. 2014
    ..The purpose of this study was to evaluate the nature of three new nucleotide changes, mutation or single nucleotide polymorphism, found in the beta-globin gene, to conduct an appropriate genetic counselling...
  20. doi Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia
    Alice Pecoraro
    Dipartimento di Oncologia ed Ematologia, U O C Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, A O Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
    Eur J Haematol 92:66-72. 2014
    ..We assessed whether the HbF response of patients with SCD and thalassemia intermedia (TI) to HU correlates with HBG (both γ-globin genes) expression in their cultured erythroid progenitors following exposure to HU...
  21. doi Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians
    Paolo Rigano
    Dipartimento di Oncologia ed Ematologia, U O C Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, A O Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy
    Am J Hematol 88:E261-4. 2013
    ..A major benefit of HU is the increase in HbF; the association of high HbF and reduced cerebrovascular disease has been weak. New treatment strategies should be developed for the prevention of sickle cerebrovascular disease...
  22. doi Co-inheritance of Hb Hershey [beta70(E14) Ala-->Gly] and Hb La Pommeraie [beta133(H11)Val-->Met] in a Sicilian subject
    Antonino Giambona
    UOC Ematologia II, AOR Villa Sofia Cervello, Palermo, Italy
    Eur J Haematol 84:453-7. 2010
    ....
  23. doi The genetic heterogeneity of β-globin gene defects in Sicily reflects the historic population migrations of the island
    Antonino Giambona
    U O C Ematologia II, A O R Villa Sofia Cervello, Palermo, Italy
    Blood Cells Mol Dis 46:282-7. 2011
    ..The origin of the large spectrum of mutations is discussed taking in consideration the history of the island...
  24. doi The significance of the hemoglobin A(2) value in screening for hemoglobinopathies
    Antonino Giambona
    U O C Ematologia II con Talassemia, Azienda Ospedaliera Vincenzo Cervello, Via Trabucco 180, 90146 Palermo, Italy
    Clin Biochem 42:1786-96. 2009
    ..Therefore, HbA(2) determination plays a key role in screening programs for hemoglobinopathy. The aim of this review is to address and suggest an approach for reducing or abolishing hemoglobinopathy screening mistakes...
  25. pmc IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection
    Vito Di Marco
    Sezione di Gastroenterologia ed Epatologia, DiBiMIS, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy
    Haematologica 97:679-86. 2012
    ..Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection...
  26. doi Chelation treatment in sickle-cell-anaemia: much ado about nothing?
    Gaetano Lucania
    U O C Ematologia II con Talassemia, A O Villa Sofia V Cervello, Palermo Dipartimento di Scienze Statistiche e Matematiche S Vianelli, Universita di Palermo, Palermo U O S Talassemia Pediatrica, A O Cardarelli, Napoli U O C Medicina Trasfusionale, A O Villa Sofia V Cervello, Palermo, Italy
    Br J Haematol 154:545-55. 2011
    ..The cost/benefit ratio has not been fully explored. Further research with larger randomized clinical trials needs to be performed...
  27. ncbi Functional characterization of the sea urchin sns chromatin insulator in erythroid cells
    Santina Acuto
    Unità di Ricerca P Cutino, Ematologia II, A O V Cervello, via Trabucco n 180 90146, Palermo, Italy
    Blood Cells Mol Dis 35:339-44. 2005
    ....
  28. pmc The sea urchin sns5 insulator protects retroviral vectors from chromosomal position effects by maintaining active chromatin structure
    Danilo D'Apolito
    Unità di Ricerca P Cutino, U O C Ematologia II, A O V Cervello, Palermo, Italy
    Mol Ther 17:1434-41. 2009
    ....
  29. ncbi Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management
    Luigi Mancuso
    Department of Cardiology, A O V Cervello Hospital, Palermo, Italy
    Expert Rev Cardiovasc Ther 1:439-52. 2003
    ..Prophylaxis of cardiomyopathy and new therapy strategies of myocardial dysfunction, including the impact of the new chelation treatment, are discussed...
  30. doi The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area
    Maria Concetta Renda
    Ematologia II Ospedale V Cervello, Palermo, Italy
    Am J Gastroenterol 103:649-55. 2008
    ..To evaluate the role of CARD15 mutations and smoking in the main events of Crohn's disease (CD)...
  31. ncbi Hb Marineo [beta70(E14)Ala-->Val]: a silent hemoglobin variant with a mutation within the heme pocket
    Antonino Giambona
    Azienda Ospedaliera Vincenzo Cervello, UO Ematologia II, Palermo, Italy
    Hemoglobin 30:139-48. 2006
    ..Reversed phase HPLC analysis showed an abnormal chain amounting to about 40% of the total beta chains...
  32. ncbi Typing of the immunological system in human embryos by coelocentesis
    Maria Concetta Renda
    Regional Center for Thalassemia, Haematology II with Thalassemia, V Cervello Hospital, Palermo, Italy
    Eur J Haematol 79:435-8. 2007
    ..These preliminary data suggest that the immunological system in human embryos could be in the ideal conditions to start a process of tolerance induction...
  33. ncbi Hepatocellular carcinoma in the thalassaemia syndromes
    Caterina Borgna-Pignatti
    Dipartimento di Medicina Clinica e Sperimentale Pediatria, University of Ferrara, Ferrara, Italy
    Br J Haematol 124:114-7. 2004
    ..Eighty-six percent had been infected by hepatitis C virus. Nineteen of 22 cases were diagnosed after 1993, suggesting that this problem is becoming more frequent with the aging population of thalassaemia patients...
  34. ncbi Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study
    Massimo Galia
    Istituto di Radiologia P Cignolini, Universita di Palermo, Palermo, Italia
    Hemoglobin 27:63-76. 2003
    ..001) was found between the gamma glutamyltransferase (gammaGt) levels and the HSIRs values. Our data confirm that heart MRI is sensitive enough to detect significant variations of the mean HSIR during iron chelation with DF or L1...
  35. ncbi The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients
    Adriana Ceci
    Dipartimento di Farmacologia, Universita di Bari, Fondazione Salvatore Maugeri, Research Institute, Pavia, Italy
    Br J Haematol 118:330-6. 2002
    ..These data show that the drug was effective in reducing serum ferritin levels and the incidence of adverse events was not greater than the frequency reported in clinical trials...
  36. ncbi Independent clinical trials
    Aurelio Maggio
    Lancet 363:1080. 2004
  37. ncbi Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*
    Alessia Pepe
    MRI Laboratory, Institute of Clinical Physiology, CNR, Pisa, Italy
    Eur J Haematol 76:183-92. 2006
    ..We set up a multislice multiecho T2* MRI for the detection of this heterogeneity. The aim of our study was to investigate differences between the L1 vs. the subcutaneous desferrioxamine (DF)-treated patients using this new approach...
  38. ncbi A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference
    Selda Samakoglu
    Laboratory of Gene Transfer and Gene Expression, Sloan Kettering Institute, New York, New York 10021, USA
    Nat Biotechnol 24:89-94. 2006
    ....
  39. ncbi Risk factors for death in patients with beta-thalassemia major: results of a case-control study
    Adriana Ceci
    Haematologica 91:1420-1. 2006
    ..The mortality risk was lower in patients with good compliance to iron chelation therapy and in those treated with deferiprone...
  40. ncbi A prospective study of hepatocellular carcinoma incidence in thalassemia
    Andrea Mancuso
    II Divisione di Ematologia, Ospedale V Cervello, Palermo, Italia
    Hemoglobin 30:119-24. 2006
    ..Further follow-up did not show any evidence of recurrence after 23 and 15 months, respectively. Ultrasound screening can allow early detection and treatment of HCC in thalassemia patients...
  41. ncbi Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy
    Michel Sadelain
    Gene Transfer and Gene Expression Laboratory, Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Gene Ther 18:1-9. 2007
  42. ncbi Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts
    Vincenzo Positano
    MRI Laboratory, Institute of Clinical Physiology, CNR, Pisa, Italy
    NMR Biomed 20:578-90. 2007
    ..The correction map failed to compensate for these variations if both additive and percentage-based corrections were applied. This may reinforce the hypothesis that true inhomogeneity in iron deposition exists...
  43. ncbi HCV clearance among hemophiliacs and beta-thalassemics
    Vito Di Marco
    Gastroenterology 132:1634. 2007
  44. ncbi Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up
    Andrea Mancuso
    Br J Haematol 133:105-6. 2006
  45. ncbi Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic
    Andrea Mancuso
    Am J Hematol 78:158-9. 2005
  46. ncbi Rapid detection of six common Mediterranean and three non-Mediterranean alpha-thalassemia point mutations by reverse dot blot analysis
    Enrica Foglietta
    Associazione Nazionale per la Lotta contro le Microcitemie in Italia, Rome, Italy
    Am J Hematol 74:191-5. 2003
    ..The method uses the principle of allele-specific oligonucleotide (ASO) hybridization, but it is a nonradioactive method and permits rapid and simultaneous typing of point mutations and small deletions...
  47. doi Guideline recommendations for heart complications in thalassemia major
    Tiziana Cogliandro
    UOSC Cardiologia, UOS, Centro della Cardiopatia nelle Talassemie, Osp S Eugenio, Roma, Italy
    J Cardiovasc Med (Hagerstown) 9:515-25. 2008
    ..Moreover, the recommendations were reviewed by two external referees before the definitive approval...
  48. doi New analytical tools and epidemiological data for the identification of HbA2 borderline subjects in the screening for beta-thalassemia
    Andrea Mosca
    CIRME, Dip di Scienze e Tecnologie Biomediche, Universita degli Studi di Milano, Via F lli Cervi 93, Segrate, Italy
    Bioelectrochemistry 73:137-40. 2008
    ....
  49. ncbi Analytical evaluation of the Tosoh HLC-723 G7 automated HPLC analyzer for hemoglobin A2 and F determination
    Renata Paleari
    Dipartimento di Scienze e Tecnologie Biomediche, Universita degli Studi di Milano, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy
    Clin Biochem 38:159-65. 2005
    ..The analytical performance of a new automated HPLC system (Tosoh HLV-723 G7) for Hb A(2) and Hb F quantification in blood was studied...
  50. doi Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patients
    Anna Ramazzotti
    Magnetic Resonance Imaging Laboratory, Institute of Clinical Physiology, CNR, Pisa, Italy
    Hemoglobin 32:97-107. 2008
    ..Moreover, it is proposed that, due to its good positive predictive value (PPV) and low cost, ECG can be a suitable guide to orient towards CMR examination in TM cases...
  51. ncbi Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies
    Aurelio Maggio
    Eur J Haematol 75:267-9. 2005